Treatment of stage 2 medication-induced osteonecrosis of the jaw: a case series

Martínez, Yanet; Pardo Zamora, Guillermo; Moreno Rodríguez, José  Antonio; Ortiz Ruiz, Antonio José

Publication:
Treatment of stage 2 medication-induced osteonecrosis of the jaw: a case series

dc.contributor.author	Martínez, Yanet
dc.contributor.author	Pardo Zamora, Guillermo
dc.contributor.author	Moreno Rodríguez, José Antonio
dc.contributor.author	Ortiz Ruiz, Antonio José
dc.contributor.department	Dermatología, Estomatología, Radiología y Medicina Física
dc.date.accessioned	2024-06-19T12:04:08Z
dc.date.available	2024-06-19T12:04:08Z
dc.date.issued	2021-01-24
dc.description	© 2021 by the authors. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in International Journal of Environmental Research and Public Health. To access the final edited and published work see https://doi.org/10.3390/ijerph18031018
dc.description.abstract	Medication-induced jaw osteonecrosis (MRONJ) is a rare and serious disease with a negative impact on patients’ quality of life, whose exact cause remains unclear and which may have a multifactorial origin. Although there are different therapeutic protocols, there is still no consensus. This case series evaluated three patients diagnosed with staged 2 MRONJ treated at the University of Murcia dental clinic according to the protocols described by the Spanish Society of Oral and Maxillofacial Surgery and the American Association of Oral and Maxillofacial Surgeons. Within 12 months of the application of therapeutic protocols, the lesions were completely healed in all cases. Radiography showed slow but progressive healing with normal bone structure. Conservative treatment with antibiotics, chlorhexidine rinses and minimally invasive surgical intervention with necrotic bone resection is effective in treating stage 2 of MRONJ. In cases of refractory osteonecrosis, the application of platelet and leukocyte-rich fibrin (PRF-L) in the surgical approach improves the outcome in soft tissue healing and bone regeneration but further research is needed to confirm its effectiveness.	es
dc.format	application/pdf	es
dc.format.extent	18	es
dc.identifier.citation	Int. J. Environ. Res. Public Health 2021, 18(3), 1018
dc.identifier.doi	https://doi.org/10.3390/ijerph18031018
dc.identifier.issn	Print: 1661-7827
dc.identifier.issn	Electronic: 1660-4601
dc.identifier.uri	http://hdl.handle.net/10201/142456
dc.language	eng	es
dc.publisher	MDPI	es
dc.relation	Sin financiación externa a la Universidad	es
dc.relation.publisherversion	https://www.mdpi.com/1660-4601/18/3/1018
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	Osteonecrosis	es
dc.subject	Medication-induced maxillary osteonecrosis	es
dc.subject	Bisphosphonates	es
dc.subject	Denosumab	es
dc.subject	Osteonecrosis treatment	es
dc.title	Treatment of stage 2 medication-induced osteonecrosis of the jaw: a case series	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es
relation.isAuthorOfPublication	39649446-591e-4ec8-9ed0-329de9b984b0
relation.isAuthorOfPublication	8ecfe223-eb89-45cd-8c87-57fa3b528c47
relation.isAuthorOfPublication	c42f35e8-5f95-4c41-b084-a18ea989caea
relation.isAuthorOfPublication.latestForDiscovery	39649446-591e-4ec8-9ed0-329de9b984b0